Boc-Aspartic α butyl ester | 124212-43-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Aspartic α butyl ester
• 英文别名: (3S)-4-butoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
• CAS: 124212-43-7
• 化学式: C₁₃H₂₃NO₆
• 分子量: 289.329
• InChiKey: FBNNIMWUQIFGRM-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Boc-L-天冬氨酸 、 正丁醇 在 papain on Sepharose 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以74%的产率得到Boc-Aspartic α butyl ester
  参考文献：
  名称：

  木瓜醇和二醇对木瓜氨酸催化酯化反应的优化

  摘要：

  讨论了醇C n H 2n + 1 OH和dioss HO（CH 2）n OH与未稳定化的木瓜蛋​​白酶（XAD-7或Sepharose）对Boc-丙氨酸和Boc-天冬氨酸的酯化作用。如果将木瓜蛋白酶包埋在XAD-7中，则Boc-Ala-OH的酯化将获得很大的改善。例如，如果使用游离木瓜蛋白酶，则用1-癸醇没有观察到酯化反应，而将木瓜蛋白酶固定在XAD-7上，则产率为55％。用木瓜蛋白酶固定在琼脂糖凝胶上，用dio1酯化Boc-Asp-OH。在乙二醇的情况下，游离木瓜蛋白酶或木瓜蛋白酶在XAD-7上未观察到缩合，而木瓜蛋白酶在琼脂糖上获得40％的酯化收率。

  DOI：

  10.1016/0040-4020(89)80104-8

文献信息

• [EN] NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX ET ANTITUMORAUX
  申请人：UNIV LEUVEN KATH

  公开号：WO2015158913A1

  公开（公告）日：2015-10-22

  The present invention relates to novel phosphate-modified nucleosides, such as phosphoramidate nucleosides. The invention also relates to the use of these novel phosphate-modified nucleosides to treat or prevent viral infections and proliferative diseases (such as cancer) and their use to manufacture a medicine to treat or prevent viral infections and proliferative diseases particularly infections with viruses belonging to the HCV family.

  本发明涉及新型磷酸酯修饰核苷，如磷酰胺酸酯核苷。该发明还涉及利用这些新型磷酸酯修饰核苷来治疗或预防病毒感染和增殖性疾病（如癌症），以及它们用于制造用于治疗或预防病毒感染和增殖性疾病，特别是感染HCV家族病毒的药物。
• 2,5-Disubstituted Piperidines
  申请人：Herold Peter

  公开号：US20090306062A1

  公开（公告）日：2009-12-10

  The application relates to 2,5-disubstituted piperidines, their preparation and use as medicines, especially as renin inhibitors, of the general formula (I) in which R, R 1 and X are each as defined in detail in the description, and pharmaceutical preparations comprising these compounds.

  该申请涉及2,5-二取代哌啶的制备和用途，特别是作为肾素抑制剂的药物。所述化合物的通式为（I），其中R、R1和X的详细定义在说明书中，以及包含这些化合物的制药制剂。
• [EN] NITRIC OXIDE-RELEASING PRODRUG MOLECULE<br/>[FR] MOLÉCULE DE PROMÉDICAMENT LIBÉRANT DE L'OXYDE NITRIQUE<br/>[ZH] 可释放一氧化氮的前药分子
  申请人：ZHEJIANG HUAHAI PHARM CO LTD

  公开号：WO2017041701A1

  公开（公告）日：2017-03-16

  一类可用于治疗心血管疾病的化合物和含有该化合物的组合物。该化合物和组合物在人体内可通过增加血液中的高密度脂蛋白胆固醇，改善脂质代谢紊乱；另一方面，该化合物和组合物还可释放出一氧化氮，通过舒张血管、降低血压、抑制血小板黏附和聚集、维持血管张力，降低心血管疾病发病风险，在防治心血管疾病的发生发展方面发挥重要作用。
• CANTACUZENE, D.;GUERREIRO, C., TETRAHEDRON, 45,(1989) N, C. 741-748
  作者：CANTACUZENE, D.、GUERREIRO, C.

  DOI：——

  日期：——
• PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS
  申请人：Schäfer Konstanze

  公开号：US20140065223A1

  公开（公告）日：2014-03-06

  The invention relates to a compound of general formula (I): A-B-C(F, G′)-D-E-F-G-A′ or a structure of general formula (II): A-B-C-(F′, G′)-D-B-E-F-G-A′ (II), wherein -A is at least one molecule selected from the group of the perfluorocarbons (PFCs), perfluorinated silicon compounds, and/or further perfluorinated compounds, -B is at least one predetermined breaking point in the form of a physically, chemically, or enzymatically severable bond, -C is absent or at least one linker molecule, -D is absent or at least one spacer molecule, -E is at least one molecule selected from the group containing nucleobases, nucleosides, nucleotides, oligonucleotides, nucleic, acids, modified nucleobases, modified nucleosides, modified nucleotides, modified oligonucleotides, modified nucleic acids, monomers of peptide nucleic acids, oligomers or peptide nucleic acids and peptide nucleic acids or other nucleic acid analogs, -F, F′ is absent or at least one ligand, -G, G′ is absent or at least one marker molecule, -A′ is absent or has the meaning of A, and wherein the compounds i), ii), iii), iv), v), vi) are excluded. The invention farther relates to the use of said compound for the non-viral transfer of molecule E into a cell, to a pharmaceutical composition containing said compound, and to the use of said pharmaceutical composition.